Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies

mAbs

Volumn 5, Issue 4, 2013, Pages 614-619

  Passot, Christophe ^a   Azzopardi, Nicolas ^a   Renault, Sylvaine ^a   Baroukh, Nadine ^a   Arnoult, Christophe ^a   Ohresser, Marc ^a   Boisdron Celle, Michèle ^b,c   Gamelin, Erick ^b   Watier, Hervé ^a,d   Paintaud, Gilles ^a,d   Gouilleux Gruart, Valérie ^a,d  

^a UNIVERSITÉ DE TOURS   (France)

^b Team 12   (France)

^c Institut de Cancérologie de l'Ouest ^*  (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Cetuximab; DNA copy number variation; FcRn; Genetic polymorphism; Neonatal Fc receptor; Pharmacokinetics; Therapeutic drug monitoring; Therapeutic monoclonal antibodies

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; IRINOTECAN;

ALLELE; ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FCGRT GENE; GENE; GENETIC POLYMORPHISM; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; VARIABLE NUMBER OF TANDEM REPEAT;

CETUXIMAB; DNA COPY NUMBER VARIATION; FCRN; GENETIC POLYMORPHISM; NEONATAL FC RECEPTOR; PHARMACOKINETICS; THERAPEUTIC DRUG MONITORING; THERAPEUTIC MONOCLONAL ANTIBODIES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; GENE DOSAGE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; JURKAT CELLS; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RECEPTORS, FC; TANDEM REPEAT SEQUENCES;

EID: 84880105371     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.24815     Document Type: Article

References (30)

1. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:1451-9; PMID:12115174; http://dx.doi.org/10.1002/art.10302
2. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66:921-6; PMID:17301106; http://dx.doi.org/10.1136/ard.2006. 065615
3. Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, et al.; IDEC-C2B8 Study Group in Japan. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13:928-43; PMID:12123339; http://dx.doi.org/10.1093/annonc/mdf155
4. Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, et al. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res 2011; 17:6329-37; PMID:21953502; http://dx.doi.org/10.1158/1078-0432.CCR-11-1081
5. Baselga J. Phase I and II clinical trials of trastuzumab. Ann Oncol 2001; 12(Suppl 1):S49-55; PMID:11521722; http://dx.doi.org/10.1093/annonc/12.suppl-1. S49
6. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45:792-801; PMID:15951469; http://dx.doi.org/10.1177/0091270005277075
7. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30:523-9; PMID:18641542
8. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009; 123:107-13, e3; PMID:19130931; http://dx.doi.org/10.1016/j.jaci.2008.09.050
9. Daydé D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009; 113:3765-72; PMID:19029438; http://dx.doi.org/10.1182/blood-2008-08-175125
10. Rodewald R, Kraehenbuhl JP. Receptor-mediated transport of IgG. J Cell Biol 1984; 99:159s-64s; PMID:6235233; http://dx.doi.org/10.1083/jcb.99.1.159s
11. Simister NE, Rees AR. Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol 1985; 15:733-8; PMID:2988974; http://dx.doi.org/10.1002/eji.1830150718
12. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003; 197:315-22; PMID:12566415; http://dx.doi.org/10.1084/jem.20021829
13. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155
14. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; http://dx.doi.org/10. 1093/intimm/13.12.1551
15. Mikulska JE, Pablo L, Canel J, Simister NE. Cloning and analysis of the gene encoding the human neonatal Fc receptor. Eur J Immunogenet 2000; 27:231-40; PMID:10998088; http://dx.doi.org/10.1046/j.1365-2370.2000.00225.x
16. Sachs UJ, Socher I, Braeunlich CG, Kroll H, Bein G, Santoso S. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology 2006; 119:83-9; PMID:16805790; http://dx.doi.org/10.1111/j.1365-2567.2006.02408.x
17. Freiberger T, Grodecká L, Ravcuková B, Kurecová B, Postránecká V, Vlcek J, et al. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency. Clin Immunol 2010; 136:419-25; PMID:20627700; http://dx.doi.org/10.1016/j.clim.2010.05.006
18. Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, et al.; DEFI study group. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol 2013; 171:186-94; PMID:23286945
19. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, et al. Large-scale copy number polymorphism in the human genome. Science 2004; 305:525-8; PMID:15273396; http://dx.doi.org/10.1126/science.1098918
20. Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat Rev Genet 2006; 7:85-97; PMID:16418744; http://dx.doi.org/10.1038/nrg1767
21. He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. Trends Mol Med 2011; 17:244-51; PMID:21388883; http://dx.doi.org/10.1016/ j.molmed.2011.01.007
22. Bender B, Bodrogi L, Mayer B, Schneider Z, Zhao Y, Hammarström L, et al. Position independent and copy-number-related expression of the bovine neonatal Fc receptor alpha-chain in transgenic mice carrying a 102 kb BAC genomic fragment. Transgenic Res 2007; 16:613-27; PMID:17594529; http://dx.doi.org/10.1007/s11248-007-9108-9
23. Nguyen DL, Staeker J, Laika B, Steimer W. TaqMan real-time PCR quantification strategy of CYP2D6 gene copy number for the LightCycler 2.0. Clin Chim Acta 2009; 403:207-11; PMID:19296901; http://dx.doi.org/10.1016/j.cca. 2009.03.007
24. Willcocks LC, Lyons PA, Clatworthy MR, Robinson JI, Yang W, Newland SA, et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med 2008; 205:1573-82; PMID:18559452; http://dx.doi.org/10.1084/jem.20072413
25. Sun YV, Peyser PA, Kardia SL. A common copy number variation on chromosome 6 association with the gene expression level of endothelin 1 in transformed B lymphocytes from three racial groups. Circ Cardiovasc Genet 2009; 2:483-8; PMID:20031624; http://dx.doi.org/10.1161/CIRCGENETICS.109.848754
26. Breunis WB, van Mirre E, Geissler J, Laddach N, Wolbink G, van der Schoot E, et al. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat 2009; 30:E640-50; PMID:19309690; http://dx.doi.org/10.1002/humu.20997
27. Wong KK, deLeeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman DE, et al. A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet 2007; 80:91-104; PMID:17160897; http://dx.doi.org/10.1086/510560
28. Perry GH, Ben-Dor A, Tsalenko A, Sampas N, Rodriguez-Revenga L, Tran CW, et al. The fine-scale and complex architecture of human copy-number variation. Am J Hum Genet 2008; 82:685-95; PMID:18304495; http://dx.doi.org/10.1016/j.ajhg. 2007.12.010
29. Baer M, Nilsen TW, Costigan C, Altman S. Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P. Nucleic Acids Res 1990; 18:97-103; PMID:2308839; http://dx.doi.org/10.1093/nar/18.1.97
30. Cézé N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. Ther Drug Monit 2009; 31:597-601; PMID:19730278; http://dx.doi.org/10.1097/FTD.0b013e3181b33da3